

## Meet the Management Series

**London, 25 February 2021** – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces a series of 2021 'Meet the Management' events for investors and analysts.

These events will be hosted by Hikma's CEO, Soggi Olafsson, and feature a presentation and Q&A with the senior leadership of each of our business segments – Injectables, Branded and Generics.

The series will kick off with Injectables on Wednesday 24 March at 14:00 GMT.

The speakers for the Injectables event will be:

Soggi Olafsson, CEO  
Riad Mishlawi, President Injectables  
Joel Rosenstack, Chief Commercial Officer, US Injectables  
Frank Savastano, General Manager, Hikma Portugal

The event will be broadcast as a webinar with a live Q&A.

Please register your attendance in advance by clicking [here](#).

Details of further events in this series will be provided in due course.

- ENDS -

### Enquiries

#### Hikma Pharmaceuticals PLC

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 7776 477050
Guy Featherstone Senior Investor Relations Manager	+44 (0)20 3892 4389/ +44 7795 896738
Layan Kalisse Investor Relations Analyst	+44 (0)20 7399 2788/ +44 7970 709912

[uk-investors@hikma.uk.com](mailto:uk-investors@hikma.uk.com)

### About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our

# hikma.

venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)